Skip to content
Pfizer logo

Pfizer

PFIZER NSE
₹3,834.70 No trade today
P/E
23.86
View as Markdown
MCP
Close 4 Nov 2026 ₹3,834.70 −1,232.80 −24.3% 1Y
Start ₹5,067.50

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
24.10%
Debt to Equity
0.02
EPS (TTM)
₹160.70
Book Value
₹918.71
Market Cap
—
P/E (TTM)
23.86
P/B
4.17
ROE
18.00%
Dividend Yield
1.96%
EBITDA
₹1,092 Cr
52W High
₹5,339.00
52W Low
₹3,589.00
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Pfizer peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Pfizer (this company)
₹3,834.7023.86₹17,805 Cr4.171.96%18.00%24.10%₹2,570 Cr₹735 Cr
Median 8 companies₹2,048.6037.20₹1,25,337 Cr4.570.70%17.25%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

59 Good

Data confidence 100/100

Category scores

Quality
75
Strong
Returns, margins, earnings quality 22% weight
Valuation
80
Strong
Cheap vs sector & own history 24% weight
Growth
36
Poor
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
16
Poor
Trend strength, vol-adjusted 12% weight
Ownership
44
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 58.3%

Weaknesses

1
  • The company has delivered a poor sales growth of 2.39% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallNeutral757
OscillatorsBullish153
Moving AveragesStrong Bearish604

Key readings

RSI (14)
48.81
Neutral
MACD (12,26,9)
−83.80
Bullish
SMA (50)
4,068.57
Bearish
SMA (200)
4,571.08
Bearish

As of

Analyst Rating

Based on 5 analysts
BUY60%

3 of 5 analysts rate Buy, 2 Hold, 0 Sell.

As of

BUY
3
60%
HOLD
2
40%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+2.28%
5Y+2.39%
3Y+1.29%
1Y+10.48%
TTM+10.64%

Net profit

Net profit growth by window
10Y+9.00%
5Y+7.71%
3Y+4.98%
1Y−5.99%
TTM−9.15%

Operating cash flow

Operating cash flow growth by window
10Y+10.87%
5Y+17.78%
3Y+39.58%
1Y+46.67%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+14.35 pp
5Y+4.07 pp
3Y+2.51 pp
1Y+3.34 pp
TTM+3.38 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,966 Cr
Mar 2018₹1,969 Cr
Mar 2019₹2,082 Cr
Mar 2020₹2,152 Cr
Mar 2021₹2,239 Cr
Mar 2022₹2,611 Cr
Mar 2023₹2,425 Cr
Mar 2024₹2,193 Cr
Mar 2025₹2,281 Cr
Mar 2026₹2,520 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹337 Cr
Mar 2018₹360 Cr
Mar 2019₹429 Cr
Mar 2020₹509 Cr
Mar 2021₹498 Cr
Mar 2022₹613 Cr
Mar 2023₹624 Cr
Mar 2024₹551 Cr
Mar 2025₹768 Cr
Mar 2026₹722 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹234 Cr −47.0% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 30 Oct 2026
AI opinion · based on fundamentals
Risk medium

Pfizer Ltd trades at ₹3,687.8 as of 2026-10-30 with a market cap of ₹16,870.85 crore, a PE of 22.95x, and a near-zero debt-to-equity ratio of 0.02. The company shows a TTM sales growth acceleration to 11% against a muted 5-year sales CAGR of 2%, while maintaining an ROE of 17.19% and a dividend yield of 1.99%.

Bull Case 7
  • Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and resilience through economic cycles
  • TTM revenue growth has accelerated sharply to 11%, a marked improvement over the 5-year compounded sales growth of just 2%, signalling a potential inflection in top-line momentum
  • Healthy return ratios with ROE at 17.19% and ROCE at 22.94%, indicating efficient capital deployment and strong profitability on invested capital
  • Consistent dividend payout ratio of 58.3% with a current dividend yield of 1.99%, offering meaningful income to shareholders
  • TTM profit growth of 14% outpaces the 3-year compounded profit growth of 8% and 5-year compounded profit growth of 9%, suggesting improving earnings trajectory
  • 10-year compounded profit growth of 10% demonstrates sustained long-term earnings compounding ability across market cycles
  • Stock is trading at ₹3,687.8, only about 2.7% above its 52-week low of ₹3,589, which may reflect much of the negative sentiment already being priced in
Bear Case 8
  • Sluggish long-term revenue growth with a 5-year compounded sales CAGR of only 2% and a 10-year CAGR of just 2%, indicating structural top-line challenges
  • Stock has declined 29% over the past 1 year and has a negative 5-year stock price CAGR of -6%, reflecting sustained erosion in market valuation
  • The stock is trading 31% below its 52-week high of ₹5,339, indicating significant downward pressure and loss of investor confidence over the trailing year
  • 3-year compounded sales growth of just 1% suggests the recent TTM uptick to 11% may not yet be confirmed as a durable trend
  • PE of 22.95x on an EPS of ₹160.7 appears elevated relative to the company's modest long-term revenue growth profile of 2% over 10 years
  • Price-to-book ratio of 4.01x implies a meaningful premium over book value, which may be difficult to sustain if growth does not accelerate durably
  • 3-year stock CAGR of -1% and 5-year stock CAGR of -6% show the stock has failed to generate positive returns for investors over medium-term horizons
  • 10-year stock CAGR of 7% lags the broader Indian market indices over the same period, suggesting relative underperformance for long-term holders

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

7d ago

TL;DR: Limited news flow for Pfizer Ltd this period. The only development is a minor ₹1.26 crore tax penalty that the company considers immaterial and intends to contest. With no significant headwinds or positive catalysts in the current cycle, the near-term outlook hinges on broader sector trends and upcoming quarterly results.

Neutral 1
  • Minor tax penalty, appeal planned Sep 29

    Pfizer India received a ₹1.26 crore penalty from the Income Tax Transfer Pricing authority for AY 2023-24. The company plans to appeal and states no material impact on financials.

Quarterly Results

₹ Cr
PFIZER quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
531
575
540
547
563
589
538
592
603
642
645
629
653
727
Expenses
421
393
387
357
385
399
392
364
393
412
417
393
406
466
Operating Profit
111
183
153
189
177
189
146
228
210
230
228
236
248
261
OPM %
21%
32%
28%
35%
32%
32%
27%
38%
35%
36%
35%
38%
38%
36%
Other Income
33
36
44
75
42
43
43
217
67
42
−20
50
45
179
Interest
3
3
3
7
2
2
2
3
3
2
2
2
1
3
Depreciation
16
15
18
14
15
15
15
16
14
14
14
15
14
14
PBT
126
201
176
244
203
215
172
426
260
255
192
269
277
423
Tax %
26%
26%
26%
27%
26%
26%
26%
22%
26%
26%
26%
26%
26%
26%
Net Profit
94
149
130
179
151
158
128
331
192
189
142
200
204
313
EPS (₹)
20.44
32.56
28.41
39.1
32.94
34.61
27.89
72.34
41.91
41.32
31
43.68
44.7
—

Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
PFIZER profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,853
2,012
1,966
1,969
2,082
2,152
2,239
2,611
2,425
2,193
2,281
2,520
2,570
Expenses
1,438
1,579
1,616
1,468
1,516
1,578
1,526
1,775
1,616
1,555
1,540
1,615
1,628
Operating Profit
414
433
350
501
566
574
712
836
809
638
742
904
942
OPM %
22%
22%
18%
25%
27%
27%
32%
32%
33%
29%
33%
36%
37%
Other Income
44
97
232
114
167
183
81
63
134
185
344
139
116
Interest
2
1
2
1
2
11
15
11
13
15
8
9.48
8
Depreciation
250
58
63
66
71
103
109
115
106
62
61
58
58
PBT
207
470
517
548
660
642
669
773
824
746
1,016
976
993
Tax %
66%
35%
35%
34%
35%
21%
26%
21%
24%
26%
24%
26%
—
Net Profit
70
305
337
360
429
509
498
613
624
551
768
722
735
EPS (₹)
15.26
66.67
73.62
78.71
93.79
111
109
134
136
121
168
158
161
Div. Payout %
82%
22%
27%
25%
24%
297%
32%
26%
29%
29%
98%
48%
—

Balance Sheet

₹ Cr
PFIZER balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
46
46
46
46
46
46
46
46
46
46
46
46
Reserves
1,927
2,118
2,373
2,637
2,966
3,350
2,347
2,819
3,162
3,550
4,172
4,157
Borrowings
2
2
2
2
2
2
63
39
41
40
108
70
Other Liabilities
638
722
840
1,004
926
1,007
810
997
752
593
585
649
Total Liabilities
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
Fixed Assets
944
925
902
950
886
973
894
869
749
713
724
678
CWIP
13
3
15
1
0
1
3
1
8
0
8
20
Investments
43
37
0
0
0
0
0
0
0
0
0
0
Other Assets
1,614
1,923
2,343
2,739
3,054
3,432
2,369
3,030
3,244
3,516
4,180
4,224
Total Assets
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922

Cash Flow

₹ Cr
PFIZER cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
113
345
329
332
98
323
427
667
356
257
660
968
Investing
68
−701
−250
−238
35
1,530
−469
−575
−36
54
−71
−562
Financing
−1
−62
−83
−110
−110
−164
−1,571
−181
−346
−235
−205
−798
Net Cash Flow
181
−417
−3
−17
23
1,690
−1,613
−88
−26
75
383
−392
Free Cash Flow
93
398
394
262
125
343
410
654
292
291
783
944
CFO/EBITDA
62
120
146
105
59
93
89
107
81
64
110
105

Ratios

PFIZER financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
32
26
20
29
30
29
18
20
23
31
31
26
Inventory Days
191
167
148
147
189
198
199
173
175
200
214
195
Days Payable
165
157
178
245
213
197
130
102
91
77
68
89
Cash Conversion Cycle
58
36
−10
−69
6
31
87
91
107
154
177
132
Working Capital Days
7
−9
−47
−57
−16
−8
3
−14
1
24
23
9
ROCE %
24%
22%
17%
21%
23%
20%
23%
29%
26%
22%
21%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Pfizer insights

65 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 63.92%
  • DIIs 17.52%
  • Public 12.20%
  • Others 4.72%
  • FIIs 1.63%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Pfizer

What does Pfizer Ltd do?
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors…
Where is Pfizer Ltd (PFIZER) listed?
Pfizer Ltd trades as PFIZER on the NSE and under code 500680 on the BSE.
Which sector does Pfizer Ltd belong to?
Pfizer Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Pfizer Ltd?
Pfizer Ltd trades at a PE ratio of 23.86 as of 4 Nov 2026, on earnings per share of ₹160.7, against a book value of ₹918.71 per share.
What is the 52-week high and low of Pfizer Ltd?
Over the last 52 weeks Pfizer Ltd has traded between ₹3,589 and ₹5,339 as of 4 Nov 2026.
Does Pfizer Ltd pay dividends?
Pfizer Ltd has a dividend yield of 1.96%.
What is the Return on Equity (ROE) of Pfizer Ltd?
Pfizer Ltd reported a return on equity of 18.00%. Its debt-to-equity ratio is 0.02.

Company Information

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. It is the 3rd largest multinational pharmaceutical company in India.

Website pfizerindia.com
CEO Ms. Meenakshi Nevatia
Employees 1,598
Listed 28 Apr 1999
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PFIZER.md for Pfizer Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month